INSULIN SENSITIZERS MARKET ANALYSIS

Global insulin sensitizers market size is projected to reach US$ 32.42  billion by 2030, from US$ 21.00 billion in 2023, at a CAGR of 6.4% during the forecast period 2023-2030.

Insulin sensitizers are a class of drugs that help the body to use insulin more effectively. These work by increasing the number of insulin receptors on cells, or by making the insulin receptors more sensitive to insulin. This helps to lower blood sugar levels in people with type 2 diabetes.

Global insulin sensitizers market growth is being driven by the increasing prevalence of type 2 diabetes. According to the data published by World Health Organization on April 5, 2023, there are over 422 million people with diabetes worldwide, and this number is expected to rise to 642 million by 2040.

Analyst’s View:

The global insulin sensitizers market has been witnessing significant growth in recent years, driven by the escalating prevalence of diabetes and related metabolic disorders. This market's trajectory is primarily shaped by the rising awareness of the importance of managing insulin resistance, a key factor in diabetes management. Insulin sensitizers, a class of drugs designed to enhance the body's response to insulin, have gained substantial traction as a vital component of diabetes treatment strategies. As healthcare systems across the world grapple with the increasing burden of diabetes, insulin sensitizers are poised to play a pivotal role in helping patients achieve better glycemic control.

Global Insulin Sensitizers Market- Regional Insights

• North America is the largest market for insulin sensitizers, accounting for around 42.5% of the global market in 2022. This is due to the high prevalence of type 2 diabetes in the region. According to the American Diabetes Association, in 2019 over 37.3 million Americans, or 11.3% of the population, had diabetes and nearly 1.9 million Americans have type 1 diabetes, including about 244,000 children and adolescents
• Europe is the second largest market for insulin sensitizers, accounting for around 28.7% of the global market in 2022. The prevalence of type 2 diabetes in Europe is also high, with over 28 million people living with the disease.
• Asia-Pacific is the fastest growing market for insulin sensitizers, accounting for around 20% of the global market in 2022. The growth of the market in this region is driven by increasing prevalence of type 2 diabetes in countries like China, India, and Indonesia.

Figure 1. Global Insulin Sensitizers Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Insulin Sensitizers Market- Drivers

• Increasing prevalence of diabetes: The rising prevalence of diabetes, particularly type 2 diabetes, is a major driver for the global insulin sensitizers market growth. Insulin sensitizers are commonly used in the management of type 2 diabetes to improve insulin sensitivity and control blood glucose levels. For instance, on April 5, 2023, according to the data published by World Health Organization, diabetes population had increased from 108 million in 1980 to 422 million by 2014, with a more rapid surge in prevalence observed in low- and middle-income nations compared to high-income countries.
• Growing global obesity epidemic: Obesity is a significant risk factor for the development of insulin resistance and type 2 diabetes. With the increasing prevalence of obesity worldwide, there is a greater need for effective insulin sensitizers to manage insulin resistance and related metabolic disorders. Moreover, according to the data published by World Health Organization, in June 2021, an 38.2 million children under the age of 5 years were overweight or obese in 2019.
• Advancements in drug development: Continuous research and development efforts have led to the introduction of new and improved insulin sensitizers in the market. These advancements include the development of novel molecules and formulation technologies, which enhance the efficacy and safety profiles of insulin sensitizing medications.
• Favorable government initiatives: Governments in various countries are implementing initiatives and programs to combat diabetes and improve patient outcomes. These initiatives often include raising awareness about diabetes, promoting early diagnosis, and providing access to affordable treatment options, including insulin sensitizers. Moreover, U.S. Department of Health and Human Services on January 25, 2023, announced that through the Indian Health Service it is investing US$139 million in funding for Special Diabetes Program for Indians (SDPI) to provide diabetes prevention and treatment services for American Indian and Alaska Native communities.

Global Insulin Sensitizers Market- Opportunities

• Emerging economies: The prevalence of diabetes is rapidly increasing in emerging economies due to changing lifestyles, urbanization, and dietary habits. These regions offer significant growth opportunities for insulin sensitizers manufacturers, as there is growing demand for effective diabetes management solutions.
• Personalized medicine: The concept of personalized medicine is gaining traction in the healthcare industry. Insulin sensitizers can play a role in personalized diabetes management by tailoring treatment plans based on individual patient characteristics, such as genetics, lifestyle, and metabolic profile. This approach presents opportunities for the development of targeted insulin sensitizers and companion diagnostic tools.
• Combination therapies: Insulin sensitizers are often used in combination with other antidiabetic medications such as insulin and oral hypoglycemic agents,to achieve optimal glycemic control. The development of innovative combination therapies involving insulin sensitizers and other drugs holds great potential in the market. Combination therapies can provide synergistic effects and address multiple aspects of insulin resistance, leading to improved patient outcomes.
• Non-diabetic applications: Insulin sensitizers have shown promise in the management of conditions other than diabetes. Research suggests that insulin sensitizers may have potential therapeutic effects for treating polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and certain types of cancer. Exploring these non-diabetic applications of insulin sensitizers could open up new avenues for market expansion.

Global Insulin Sensitizers Market- Trends

• Increasing adoption of novel insulin sensitizers: The market has witnessed introduction and adoption of novel insulin sensitizers that offer improved efficacy, safety profiles, and convenience of use. These include newer generations of thiazolidinediones (TZDs) such as pioglitazone, as well as other classes of drugs, such as sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), which have shown insulin-sensitizing effects in addition to their primary mechanisms of action. These newer options provide alternative treatment choices and expand the range of available insulin sensitizers.
• Focus on combination therapies: Combination therapies involving insulin sensitizers are gaining prominence in the management of diabetes. Combining insulin sensitizers with other antidiabetic agents, such as insulin, metformin, or dipeptidyl peptidase-4 (DPP-4) inhibitors, can provide synergistic effects and achieve better glycemic control. Combination therapies are being explored and optimized to address the complex pathophysiology of insulin resistance and maximize treatment outcomes.
• Shift towards precision medicine: Precision medicine approaches, tailored to individual patient characteristics, are becoming increasingly important in diabetes management. Insulin sensitizers are being used in personalized treatment strategies based on factors like genetic markers, metabolic profiles, and response patterns. Advancements in molecular biology, genetics, and biomarker research are paving the way for precision medicine approaches in selecting appropriate insulin sensitizers and optimizing therapy for better patient outcomes.
• Rising preference for once-daily dosing: The market is witnessing a shift towards once-daily dosing regimens for insulin sensitizers, offering greater convenience and improved patient compliance. Extended-release formulations of certain insulin sensitizers, such as metformin and pioglitazone, allow once-daily administration and provide sustained drug release throughout the day. This trend is aimed at simplifying treatment regimens and enhancing patient adherence.

Global Insulin Sensitizers Market- Restraints

• Adverse effects and safety concerns: Insulin sensitizers, like any other medications, can have potential adverse effects and safety concerns. Certain classes of insulin sensitizers, such as thiazolidinediones (TZDs), have been associated with side effects like weight gain, fluid retention, bone fractures, and increased risk of heart failure. These safety concerns can limit their use and pose challenges to their widespread adoption. For instance, on February 20, 2023, according to the data published by National Center for Biotechnology Information, there are several undesirable side effects to thiazolidinediones, particularly with long-term use which includes edema and congestive heart failure, weight gain, fractures, and others.
• Limited efficacy in certain patient populations: Insulin sensitizers may have varying degrees of efficacy in different patient populations. Factors like genetics, age, ethnicity, and underlying metabolic conditions can influence individual responses to insulin sensitizers. Some patients may not respond adequately to certain insulin sensitizers, leading to suboptimal glycemic control. Identifying alternative treatment options for non-responders remains a challenge.
• Regulatory challenges and market access: Regulatory requirements and processes for the approval of insulin sensitizers can be complex and time-consuming. Stringent regulatory guidelines, particularly in developed countries, may slow down the introduction of new insulin sensitizers to the market. Market access barriers, such as reimbursement policies and formulary restrictions, can also limit patient access to certain insulin sensitizers, impacting their adoption.
• Cost and affordability: The cost of insulin sensitizers can be a significant barrier to their widespread use, particularly in low- and middle-income countries. Insulin sensitizers, especially newer or branded medications, can be expensive, and thus, placing a financial burden on patients. Affordability issues can hinder access to optimal treatment and contribute to suboptimal glycemic control in some populations.
• Moreover, increasing various organic strategies such as product launch and product approvals are expected to drive the market growth over the forecast period.

Recent Developments

New product launches

• In June 2021, U.S. Food and Drug Administration approved Wegovy (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol) The FDA granted the approval to Novo Nordisk, one of the global biopharmaceutical company.

Acquisition and partnerships

• On September 19, 2023, Novo Nordisk, one of the leading global healthcare company, announced its partnership with Aspen SA Operations (Pty) Ltd., one of the global specialty and branded multinational pharmaceutical company, to establish human insulin production in South Africa
• In April 2022, Abbott, one of the global healthcare leader, CamDiab, a digital health and personalized medicine company, and Ypsomed, one of the leading developer and manufacturer of injection and infusion systems, announced that all are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to lessen the burden of round-the-clock diabetes management for people with diabetes
• In December 2022, Eli Lilly and Company, one of the global biopharmaceutical company, and EVA Pharma, a pharmaceutical company, announced collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa

Figure 2. Global Insulin Sensitizers Market Share (%), By Type, 2023

To learn more about this report, request sample copy

Top companies in Global Insulin Sensitizers Market

• Eli Lilly and Company
• Novo Nordisk
• Sanofi
• Merck & Co.
• Bristol Myers Squibb
• AstraZeneca
• Boehringer Ingelheim
• Johnson & Johnson
• Takeda Pharmaceutical

Definition: Global insulin sensitizers market refers to the pharmaceutical products or interventions that are designed to improve insulin sensitivity in individuals with conditions such as insulin resistance, type 2 diabetes, metabolic syndrome, and polycystic ovary syndrome (PCOS). Insulin Sensitizers help the body to utilize insulin more effectively, leading to improved glucose control and metabolic outcomes. The market encompasses various types of insulin sensitizers, including medications, therapies, and related products, as well as the research, development, manufacturing, and distribution activities associated with them